Janus kinase inhibitors and risk of internal malignancy in dermatomyositis

Janus kinase inhibitors and risk of internal malignancy in dermatomyositis

Bibliographic Details
Main Authors:	Antonio Ji-Xu, Stephanie T. Le, Emanual Maverakis
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-08-01
Series:	Journal of Dermatological Treatment
Online Access:	http://dx.doi.org/10.1080/09546634.2022.2089323

Similar Items

Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China
by: Junmei Zhang, et al.
Published: (2023-10-01)

Itch and Janus Kinase Inhibitors
by: Yujin Han, et al.
Published: (2023-02-01)

Janus kinase inhibitors: jackpot or potluck?
by: Pavithran Keechilat, et al.
Published: (2012-06-01)

Janus Kinase Inhibitors and Cell Therapy
by: Amer Assal, et al.
Published: (2021-08-01)

RUSSIAN AND INTERNATIONAL EXPERIENCE IN THE APPLICATION OF THE JANUS-KINASES INHIBITOR IN RHEUMATOID ARTHRITIS
by: D. E. Karateev, et al.
Published: (2017-05-01)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
by: Fabienne Ballanger, et al.
Published: (2023-06-01)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
by: Sylwia Słuczanowska-Głąbowska, et al.
Published: (2021-09-01)

Janus Kinase inhibitors in dermatology: a review
by: Bárbara Vieira-Granja, et al.
Published: (2023-01-01)

Janus kinase inhibitors in autoimmune bullous diseases
by: Dawei Huang, et al.
Published: (2023-07-01)

Janus Kinase Inhibitors in the Treatment of Alopecia Areata
by: Athanasios J. Stefanis
Published: (2023-02-01)

Janus Associated Kinases Inhibitors in the Pharmacological Thera
by: Daniela Santos1, et al.
Published: (2017-01-01)

Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)

Janus kinase inhibitors in immunoinflammatory rheumatic diseases
by: Evgeny L. Nasonov
Published: (2022-06-01)

Vesiculo-bullous Dermatomyositis in Association with Internal Malignancy
by: T. Mori, et al.
Published: (2022-11-01)

Janus kinase inhibitors: between prescription authorization and reimbursability
by: F.R. Spinelli, et al.
Published: (2023-12-01)

Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
by: Izabella Ryguła, et al.
Published: (2023-12-01)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
by: David Nash, BHSc, et al.
Published: (2023-02-01)

Role of janus kinase inhibitors in the treatment of alopecia areata
by: Triyangkulsri K, et al.
Published: (2018-07-01)

Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
by: Fei Qi, et al.
Published: (2021-11-01)

Janus kinase inhibitors - their current applications and future prospects
by: Natalia Wierzbowska, et al.
Published: (2022-09-01)

Research progress on risk factors for dermatomyositis with malignancy
by: Juanjuan PAN, et al.
Published: (2023-04-01)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
by: Singer J, et al.
Published: (2016-08-01)

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
by: Robert Roskoski, Jr.
Published: (2022-09-01)

In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones
by: Kamonpan Sanachai, et al.
Published: (2023-01-01)

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
by: Eric Toussirot
Published: (2022-02-01)

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
by: Peter J. Richardson, et al.
Published: (2023-10-01)

The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
by: Jin-Woo Kim, et al.
Published: (2021-10-01)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
by: Ulrike Blume-Peytavi, et al.
Published: (2015-04-01)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
by: Miao Chen, et al.
Published: (2020-04-01)

Janus Kinases in Leukemia
by: Juuli Raivola, et al.
Published: (2021-02-01)

Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease
by: Huo R, et al.
Published: (2022-04-01)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
by: Dionysis Nikolopoulos, et al.
Published: (2023-06-01)

Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study
by: Sun-Young Jung, et al.
Published: (2022-12-01)

Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics
by: Oh Chan Kwon, et al.
Published: (2024-04-01)

Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics
by: Valentina Pala, et al.
Published: (2023-12-01)

Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses
by: Qingying He, et al.
Published: (2024-02-01)

Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis
by: Giuseppe Cuccia, et al.
Published: (2024-01-01)

Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis
by: Marino Paroli, et al.
Published: (2023-01-01)

Docking and Selectivity Studies of Covalently Bound Janus Kinase 3 Inhibitors
by: Haizhen A. Zhong, et al.
Published: (2023-03-01)

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
by: Huo R, et al.
Published: (2023-04-01)